Publications by authors named "Talanki Lokesh Pooja"
CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.
Manoj Kumar Sadasivuni Bobbili Madhusudhan Reddy Jaideep Singh Mammen O Anup Venkategowda Sunil Talanki Lokesh Pooja
Diabetol Metab Syndr
August 2014
Article Synopsis
- Retinoid X Receptors (RXR) play important roles in regulating metabolism, and rexinoids that activate RXR are being explored as treatments for metabolic syndrome; however, some past rexinoids caused adverse effects like increased triglycerides and liver issues.
- This study focuses on evaluating a new rexinoid, CNX-013-B2, for treating metabolic syndrome by selectively activating specific RXR partner pathways to improve insulin resistance.
- Results showed that CNX-013-B2 led to significant reductions in glucose and cholesterol levels in both ob/ob and high-fat diet mice, suggesting its potential benefits for managing metabolic risk factors.